Individuals with HIV and latent TB are at a significantly higher risk of developing active TB, with a higher mortality rate compared with those who are HIV-negative with latent TB. This risk can be mitigated by increasing access to antiretroviral therapy (ART) and diagnostic testing for latent TB, and increased access to latent TB treatment.
A review, published in Infectious Disease Special Edition, provides an overview of treatment recommendations of the US Department of Health and Human Services (HHS) in individuals with HIV and latent TB, focusing on important considerations that need to be considered in those on ART.
Access the full review here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #14, 21 December 2024).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and EATG. Subscribe to the newsletter here.
Source : Infectious Disease Special Edition
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.